Turnover: 42.997 billion USD (2022)

Country: France

A French pharmaceutical company of international stature

News

Sanofi plans to spin off its Consumer Healthcare business in 2024 28/10/2023

  • Year of separate listing of Sanofi's Consumer Healthcare Division: 2024
  • Sanofi envisages savings of: up to 2 billion euros between 2024 and the end of 2025
  • Presence of Sanofi Consumer Healthcare Division: 150 countries, more than 11,000 employees

Sanofi to spin off its consumer healthcare division and float it on the stock market 27/10/2023

  • Sanofi is a French pharmaceutical company
  • The Consumer Healthcare division has over 11,000 employees in 150 countries.
  • The demerger of Consumer Healthcare will take place in the fourth quarter of 2024 at the earliest.
  • This division accounts for just over 10% of Group sales.
  • In 2022, the Consumer Healthcare division generated 5.1 billion euros of Sanofi's 43 billion euros in sales.
  • The Consumer Healthcare division posted growth of 13.7% in 2022.
  • By 2021, the global consumer healthcare market will be worth over €180 billion.
  • The market share of Haleon, the world leader in consumer healthcare, is estimated at 6% in 2021.
  • The over-the-counter segment accounts for 90 billion euros, vitamins, minerals and supplements for 50 billion euros, and oral care for almost 30 billion euros.
  • Its Dupixent sales approach 11 billion euros in annual sales.
  • Beyfortus vaccine is currently marketed in 4 countries, including France.

Sanofi inaugurates Europe's largest vaccine plant at Val-de-Reuil 07/09/2023

  • Sanofi's vaccine plant in Val-de-Reuil celebrated its 50th anniversary.
  • Sanofi has invested 250 million euros in two modernization/expansion projects at the plant, which employs 2,200 people.
  • It ships 600 million doses of vaccines worldwide every year.
  • Sanofi has set up a new influenza vaccine production unit, at a cost of 200 million euros.
  • Over the past ten years, Sanofi has invested 600 million euros in Val-de-Reuil.
  • Sanofi plans to double sales of its vaccines division between 2018 and 2030, to more than 10 billion euros a year.

Sanofi invests $250 million in flu vaccines in France | Sanofi invests $250 million in flu vaccines in France 07/09/2023

  • Sanofi is the world's fourth-largest vaccines company
  • Sanofi invests 250 million euros in its Val-de-Reuil site, Europe's largest vaccine production facility
  • Sanofi has 11 vaccine plants
  • 50% of Sanofi's production is concentrated in influenza.
  • Sanofi increases influenza vaccine production capacity by 40%
  • Sanofi's Efluelda vaccine is recommended for the elderly and launched in 18 countries, including 11 where it has been recommended by health authorities.
  • Sanofi has invested over 600 million euros in its Val-de-Reuil site over the past ten years.

Sanofi gains a foothold in the obesity market with biotech Adocia 10/07/2023

  • Appetite suppressants derived from antidiabetics are an emerging market
  • . Industry giants such as American Lilly and Danish Novo Nordisk are already involved in this market.
  • Sanofi paid 10 million for the exclusive right to negotiate a worldwide partnership for Adocia's M1Pram rapid insulin.
  • Adocia's M1Pram rapid insulin is special in that it makes you lose weight instead of gaining it.
  • The potential market for appetite suppressants derived from antidiabetics is estimated at several tens of billions of dollars a year.
  • Sanofi is a specialist in type 1 diabetes, and M1Pram could benefit obese patients suffering from this type of diabetes - around 5% of type 2 diabetics.
  • Phase 2 clinical results for M1Pram showed exceptional weight loss with good glycemic control in overweight and obese type 1 diabetics.
  • The population that could benefit from M1Pram is estimated at nearly 40 million people worldwide, representing a potential market worth several billion dollars.

Sanofi finally has its Covid-19 vaccine 13/11/2022

  • Doses ready for distribution
  • The French laboratory has accepted the dominance of the RNA vaccine and the American Moderna and German BioNTech
  • The recombinant protein technology used in its VidPrevtyn Beta will make it possible to vaccinate populations in regions where the cold chain is difficult to maintain

Financial Data

DUNS: 403335904

Legal Name: SANOFI-AVENTIS FRANCE

Address: 82 AV RASPAIL , 94250 GENTILLY

Number of employees: Entre 2 000 et 4 999 salariés (2020)

Capital: 645 777 EUR


Financial Data:

Year 2021 2020 2019 2018 2017 2016 2015
Turnover 1 580 000 000 1 743 000 000 1 795 000 000 1 981 000 000 2 123 000 000 1 837 000 000 1 937 000 000
Gross margin (€) 777 000 000 805 000 000 3 079 000 000 862 000 000 3 482 000 000 3 141 000 000 -
EBITDA (€) 201 000 000 207 000 000 104 000 000 88 000 000 127 000 000 3 867 000 000 -
Operating profit (€) 175 000 000 186 000 000 174 000 000 88 000 000 163 000 000 245 000 000 -
Net profit (€) 142 000 000 159 000 000 -29 000 000 92 000 000 113 000 000 66 000 000 105 000 000
Turnover growth rate (%) -9,4 -2,9 -9,4 -6,7 15,6 -5,2 -
Ebitda margin rate (%) 12,7 11,9 5,8 4,4 6 - -
Operating margin rate (%) 11,1 10,7 9,7 4,4 7,7 - -
Working Capital (turnover days) 125,7 133 104,2 -26,5 -16,5 - -
Working Capital requirements (turnover days) 16,4 38,3 33,8 -7,2 2,9 - -
Net margin (%) 9 9,1 -1,6 4,6 5,3 - -
Added value / Turnover (%) 29,6 29,7 174,2 22,6 176,9 - -
Wages and social charges (€) 229 000 000 253 000 000 -296 000 000 383 000 000 -308 000 000 -292 000 000 -
Salaries / Turnover (%) 14,5 14,5 -16,5 19,3 -14,5 - -

Company Managers:

Position First Name Last Name Age Linkedin
Président du conseil d'administration, Directeur général, Administrateur Audrey DUVAL 46
Directeur général délégué Jean-Marc LACROIX 53
Directeur général délégué Emmanuelle FOUCHS 56

Studies mentioning this company

The food supplements market - Italy

Other companies mentioned:

The pharmacy market - France

Other companies mentioned:

The pharmacy market - Spain

Other companies mentioned:

  • Sanofi Aventis
  • Novartis
  • Hygie 31- Laf Santé
  • Johnson & Johnson
  • Pfizer
  • Roche Groupe
  • Cofares S.c. Farmaceutica Española
  • Grupo Bidafarma S.c. Andaluza De Segundo Grado
  • Alliance Healthcare España Sociedad Anonima
  • Hermandad Farmaceutica Del Mediterraneo S.c.l.
  • Grupo Unnefar S.c.
  • Janssen Cilag Sa
  • Merck Sharp & Dohme De España Sau
  • Almirall

> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)

 

Ask Sector-GPT  

Sector-GPT est la première IA dédiée aux informations sectorielles.